Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and Bulgaria, Mannkind has released new data from a Phase 3 bioequivalence study of its Afrezza inhaled insulin. The new data concern the equivalence of Afrezza delivered by the company’s original MedTone device and the new Gen2 delivery device. Read the company’s press release regarding the lawsuit. Read the company’s press release. announcing study results.
